Live Analyst Rating Changes 28708 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jeff Jones
OPCO

Jeff Jones

Oppenheimer
Wall Street Analyst
★★★★★
#218
on 13Foresight · ranked by our own returns
61%
Success Rate
+10.6%
Average Return
25 of 41 calls profitable · +59.2% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 61% of Jeff Jones's ratings turned a profit when each position was held for 1 year — averaging +10.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

85 Buy 8 Hold 0 Sell
Jeff's Stock Coverage 32 ratings · 2026-08-31
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AAPG
Ascentage Pharma Group International Unsponsored ADR
 Aug 21, 2026 BUY Strong Buy
+153.5% avg upside
10 analysts
$45.00
146.24% Upside
 +10.2% ·
PMVP
PMV Pharmaceuticals
 Aug 17, 2026 BUY Strong Buy
+1104.8% avg upside
12 analysts
$5.00
309.88% Upside
 -0.8% ·
PTHS
Pelthos Therapeutics
 Aug 14, 2026 BUY Strong Buy
+113.3% avg upside
8 analysts
$64.00
158.72% Upside
 -9.1% ·
MDWD
Mediwound
 Aug 14, 2026 BUY Strong Buy
+69.1% avg upside
13 analysts
$30.00
136.95% Upside
 -6.6% ·
ACRV
Acrivon Therapeutics, Inc.
 Aug 13, 2026 BUY Strong Buy
+599.0% avg upside
13 analysts
$8.00
288.36% Upside
 +16.2% ·
AVBP
ArriVent BioPharma, Inc.
 Aug 13, 2026 BUY Strong Buy
+40.9% avg upside
15 analysts
$50.00
65.75% Upside
 +0.8% ·
CATX
Perspective Therapeutics
 Aug 11, 2026 BUY Strong Buy
+255.0% avg upside
22 analysts
$13.00
318.04% Upside
 -2.2% ·
CRBP
Corbus Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+219.5% avg upside
20 analysts
$48.00
339.95% Upside
 +7.3% ·
CRVS
Corvus Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+80.4% avg upside
14 analysts
$33.00
132.98% Upside
 +1.7% ·
BCYC
Bicycle Therapeutics
 Jul 31, 2026 BUY Strong Buy
+474.1% avg upside
21 analysts
$11.00
161.83% Upside
 +12.2% ·
ALMS
Alumis Inc.
 Jul 15, 2026 BUY Strong Buy
+71.1% avg upside
11 analysts
$55.00
145.83% Upside
 -19.4% ·
ODTX
Odyssey Therapeutics, Inc.
 Jun 18, 2026 BUY Strong Buy
+46.8% avg upside
6 analysts
$40.00
64.23% Upside
 +36.2% ·
CMMB
Chemomab Therapeutics
 May 15, 2026 BUY Strong Buy
+903.7% avg upside
6 analysts
$25.00
822.53% Upside
 +63.9% ·
PHVS
Pharvaris
 May 13, 2026 BUY Strong Buy
+31.4% avg upside
15 analysts
$50.00
41.61% Upside
 +12.3% ·
WHWK
Whitehawk Therapeutics
 May 08, 2026 BUY Strong Buy
+169.9% avg upside
14 analysts
$7.00
51.46% Upside
 +28.0% ·
ACRS
Aclaris Therapeutics
 May 08, 2026 BUY Strong Buy
+66.4% avg upside
15 analysts
$10.00
66.38% Upside
 +21.9% ·
PHAR
Pharming Group
 May 08, 2026 BUY Strong Buy
+231.2% avg upside
4 analysts
$40.00
241.86% Upside
 -9.2% ·
IMCR
Immunocore Holdings
 Apr 20, 2026 BUY Strong Buy
+75.9% avg upside
22 analysts
$86.00
134.90% Upside
 +16.8% ·
CLRB
Cellectar Biosciences
 Mar 02, 2026 HOLD Buy
+2811.7% avg upside
8 analysts
 — -15.4% ·
KYMR
Kymera Therapeutics
 Feb 27, 2026 BUY Strong Buy
-9.8% avg upside
37 analysts
$120.00
1.51% Upside
 +31.6% ·
ZURA
Zura Bio
 Aug 15, 2025 BUY Strong Buy
+176.2% avg upside
13 analysts
$16.00
179.72% Upside
 +235.5% ·
ABEO
Abeona Therapeutics
 Aug 14, 2025 BUY Strong Buy
+188.3% avg upside
17 analysts
$20.00
237.80% Upside
 -17.2% ·
PLRX
Pliant Therapeutics
 Aug 08, 2025 HOLD Buy
+1907.6% avg upside
21 analysts
 — -36.8% ·
MCRB
Seres Therapeutics
 Oct 29, 2024 HOLD Buy
+224.3% avg upside
11 analysts
 — +9.5% ·
ANTX
AN2 Therapeutics, Inc.
 Aug 14, 2024 HOLD Buy
+57.7% avg upside
8 analysts
 — +0.5% ·
MBRX
Moleculin Biotech
 Nov 30, 2023 BUY Strong Buy
+1977.2% avg upside
5 analysts
 — · ·
BGMS
Bio Green Med Solution
 Nov 07, 2023 BUY Strong Buy
+1440.7% avg upside
7 analysts
 — · ·
NOVN
Novan
 Jul 18, 2023 HOLD Hold
6 analysts
 — · ·
EVAX
Evaxion Biotech
 Apr 28, 2023 BUY Strong Buy
+318.5% avg upside
6 analysts
 — -66.8% ·
NTBLQ
Notable Labs
 Jul 20, 2022 HOLD Buy
+809999900.0% avg upside
12 analysts
 — · ·
TRVN
Trevena
 Sep 30, 2021 HOLD Buy
+1424900.0% avg upside
11 analysts
 — · ·
JEF
Jefferies
 Jun 22, 2021 BUY Buy
-9.7% avg upside
9 analysts
$37.00
30.36% Downside
 -6.9% ·
🔒 27 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jeff Jones — Frequently Asked Questions
How accurate are Jeff Jones's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Jeff's ratings were profitable over a one-year hold, with an average return of +10.7% per rating, or +53.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jeff ranked on 13Foresight?
Jeff Jones is currently ranked #218 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jeff cover?
Jeff most recently has ratings on AAPG, PMVP, PTHS, MDWD, ACRV, AVBP, CATX, CRBP, CRVS, BCYC, ALMS, ODTX and 20 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.